Comparison of the therapeutic responsiveness of patients with BP180-reactive bullous pemphigoid (BP) and patients with BP230-reactive BP.

Recruiting

• Conditions: L12.0; Bullous pemphigoid

• Registration Number: DRKS00029671
• Lead Sponsor: Department of Dermatology University Hospital, Ruprecht-Karls-University Heidelberg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-19
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 45

Inclusion Criteria

Clinic compatible with bullous pemphigoid
- Positive direct immunofluorescence findings (linear IgG and/or C3 deposition).
- Depending on the subcollective, positive or negative commercial BP180, respectively BP230 ELISA.
- Initial diagnosis of bullous pemphigoid

Exclusion Criteria

- Lack of legal capacity
- Lack of consent
- Correctional system
- Patients <18 years
- Pregnancy/nursing period
- Evidence of linear IgA or IgM pattern in direct immunofluorescence.
- Bullous pemphigoid-associated therapy within the past 6 months (except local class 1 or 2 steroid therapy for less than 7 days).
- Predominant or isolated mucosal involvement.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to disease control (3 days no new skin lesions). Observation period 30 days.

Secondary Outcome Measures

Name	Time	Method
Extent of disease (BPDAI score, BPDAI pruritus component), recurrence rate, quantification of epitope-spreading phenomena in case of recurrence. 1 year observation period after initial diagnosis.